Daniel P. Sutherlin

6.0k total citations · 2 hit papers
32 papers, 3.1k citations indexed

About

Daniel P. Sutherlin is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Daniel P. Sutherlin has authored 32 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 8 papers in Organic Chemistry and 6 papers in Oncology. Recurrent topics in Daniel P. Sutherlin's work include Carbohydrate Chemistry and Synthesis (6 papers), Glycosylation and Glycoproteins Research (5 papers) and Chemical Synthesis and Analysis (5 papers). Daniel P. Sutherlin is often cited by papers focused on Carbohydrate Chemistry and Synthesis (6 papers), Glycosylation and Glycoproteins Research (5 papers) and Chemical Synthesis and Analysis (5 papers). Daniel P. Sutherlin collaborates with scholars based in United States, France and Switzerland. Daniel P. Sutherlin's co-authors include Guy S. Salvesen, Kelly M. Boatright, Fiona L. Scott, Wade Edris, Sabina Sperandio, Martin Renatus, Jean‐Ehrland Ricci, Hwain Shin, Irene M. Pedersen and Douglas R. Green and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Daniel P. Sutherlin

31 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Timothy R. Wilson, Jane Fridlyand et al. Nature profile →
A Unified Model for Apical Caspase Activation

2003 739 citations Kelly M. Boatright, Martin Renatus et al. Molecular Cell profile →

Peers

Countries citing papers authored by Daniel P. Sutherlin

Since Specialization

Citations

This map shows the geographic impact of Daniel P. Sutherlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Sutherlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Sutherlin more than expected).

Fields of papers citing papers by Daniel P. Sutherlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Sutherlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Sutherlin. The network helps show where Daniel P. Sutherlin may publish in the future.

Co-authorship network of co-authors of Daniel P. Sutherlin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Sutherlin. A scholar is included among the top collaborators of Daniel P. Sutherlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Sutherlin. Daniel P. Sutherlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nav1.7 inhibitors for the treatment of chronic pain 2018 ·Bioorganic & Medicinal Chemistry Letters ·Steven J. McKerrall, Daniel P. Sutherlin	29
2	Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors 2018 ·Proceedings of the National Academy of Sciences ·Tania Chernov-Rogan, Tianbo Li, Gang Lü, (unknown), Kuldip Khakh, Steven W. Jones, Maureen H. Beresini, Chang Liu, Daniel F. Ortwine, Steven J. McKerrall, David H. Hackos, Daniel P. Sutherlin, Charles J. Cohen, Jun Chen	25
3	Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles 2017 ·ACS Medicinal Chemistry Letters ·Brian S. Safina, Richard L. Elliott, Andrew K. Forrest, Robert A. Heald, Jeremy Murray, Jim Nonomiya, Jodie Pang, Laurent Salphati, Eileen M. Seward, Steven T. Staben, Mark Ultsch, BinQing Wei, Wenqian Yang, Daniel P. Sutherlin	22
4	Structural Basis of Nav1.7 Inhibition by an Isoform-Selective Small Molecule Antagonist 2016 ·Biophysical Journal ·David H. Hackos, Shivani Ahuja, Susmith Mukund, Lunbin Deng, Kuldip Khakh, Elaine Chang, Clint Young, Sophia Lin, J. P. Johnson, Daniel F. Ortwine, Brian S. Safina, Daniel P. Sutherlin, Charles J. Cohen, Christopher M. Koth, Jian Payandeh	2
5	Investigation of Dose-Dependent Factors Limiting Oral Bioavailability: Case Study With the PI3K-δ Inhibitor 2016 ·Journal of Pharmaceutical Sciences ·Po‐Chang Chiang, Daniel P. Sutherlin, Jodie Pang, Laurent Salphati	1
6	Discovery and preclinical development of vismodegib 2014 ·Expert Opinion on Drug Discovery ·Stephen E. Gould, Jennifer A. Low, James C. Marsters, Kirk Robarge, Lee L. Rubin, Frédéric J. de Sauvage, Daniel P. Sutherlin, Harvey Wong, Robert L. Yauch	54
7	Identification of GNE-293, a potent and selective PI3Kδ inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity 2013 ·Bioorganic & Medicinal Chemistry Letters ·Brian S. Safina, Zachary K. Sweeney, Jun Li, Bryan Chan, Angelina Bisconte, Diane E. Carrera, Georgette M. Castanedo, Michael Flagella, Robert A. Heald, Cristina Lewis, Jeremy Murray, Jim Nonomiya, Jodie Pang, Steve Price, Karin Reif, Laurent Salphati, Eileen M. Seward, BinQing Wei, Daniel P. Sutherlin	25
8	Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor 2012 ·Toxicology and Applied Pharmacology ·Dolores Diaz, Kevin A. Ford, Dylan P. Hartley, Eric B. Harstad, Gary Cain, (unknown), Trung Van Nguyen, (unknown), Zhong Zheng, Mark Merchant, Daniel P. Sutherlin, John J. Gaudino, (unknown), (unknown), Edna F. Choo, Bianca M. Liederer, Donna M. Dambach	22
9	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors breakdown → 2012 ·Nature ·Timothy R. Wilson, Jane Fridlyand, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman, Antoni Ribas, Li Jiang, John G. Moffat, Daniel P. Sutherlin, Hartmut Koeppen, Mark Merchant, Richard M. Neve, Jeff Settleman	884
10	Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors 2011 ·Xenobiotica ·Bianca M. Liederer, Xingrong Liu, Leonid M. Berezhkovskiy, Gary Cain, Xiao Ding, John J. Gaudino, (unknown), Emile G. Plise, Daniel P. Sutherlin, Eric B. Harstad	1
11	On The Edge of Validation – Cancer Protease Fibroblast Activation Protein 2008 ·Mini-Reviews in Medicinal Chemistry ·Beni B. Wolf, Clifford Quan, (unknown), Christian Wiesmann, Daniel P. Sutherlin	29
12	A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo 2005 ·Journal of Biological Chemistry ·Alan G. Olivero, Charles Eigenbrot, Richard Goldsmith, Kirk Robarge, Dean R. Artis, John A. Flygare, Thomas E. Rawson, Daniel P. Sutherlin, Saloumeh Kadkhodayan, Maureen H. Beresini, Linda O. Elliott, (unknown), David W. Banner, Mark Ultsch, Ulla M. Marzec, Stephen R. Hanson, Canio J. Refino, Stuart Bunting, Daniel Kirchhofer	36
13	CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leads 2005 ·Bioorganic & Medicinal Chemistry Letters ·Georgette M. Castanedo, Kevin Clark, Shumei Wang, Vickie Tsui, Mengling Wong, John B. Nicholas, Dineli Wickramasinghe, James C. Marsters, Daniel P. Sutherlin	28
14	Activation of caspases-8 and -10 by FLIPL 2004 ·Biochemical Journal ·Kelly M. Boatright, (unknown), Jean‐Bernard Denault, Daniel P. Sutherlin, Guy S. Salvesen	192
15	A Substrate-Phage Approach for Investigating Caspase Specificity 2004 ·The Protein Journal ·Samantha Lien, Richard W. Pastor, Daniel P. Sutherlin, Henry B. Lowman	33
16	A Unified Model for Apical Caspase Activation breakdown → 2003 ·Molecular Cell ·Kelly M. Boatright, Martin Renatus, Fiona L. Scott, Sabina Sperandio, Hwain Shin, Irene M. Pedersen, Jean‐Ehrland Ricci, Wade Edris, Daniel P. Sutherlin, Douglas R. Green, Guy S. Salvesen	739
17	Combinatorial Chemistry in Steroid Receptor Drug Discovery 2003 ·Humana Press eBooks ·John A. Flygare, Daniel P. Sutherlin, S. David Brown	0
18	Solid-phase synthesis of dual α4β1/α4β7 integrin antagonists: two scaffolds with overlapping pharmacophores 2002 ·Bioorganic & Medicinal Chemistry Letters ·Georgette M. Castanedo, (unknown), (unknown), John B. Nicholas, (unknown), Kevin Clark, Susan M. Keating, Maureen H. Beresini, Henry Chiu, Sherman Fong, James C. Marsters, David Y. Jackson, Daniel P. Sutherlin	9
19	Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors 1999 ·Chemistry & Biology ·Young‐Tae Chang, Nathanael S. Gray, Gustavo R. Rosania, Daniel P. Sutherlin, Soojin Kwon, Thea Norman, (unknown), Maryse Leost, Laurent Meijer, Peter G. Schultz	226
20	Generation of C-Glycoside Peptide Ligands for Cell Surface Carbohydrate Receptors Using a Four-Component Condensation on Solid Support 1996 ·The Journal of Organic Chemistry ·Daniel P. Sutherlin, (unknown), Robert G. Hughes, Robert W. Armstrong	81

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact